紫杉醇是乳腺癌转移治疗的主要药物，通常耐受性良好，因此在转移过程中重新使用（重新挑战）是具有吸引力的治疗选择。鉴于目前文献的缺乏，我们怀疑在曾经接受过紫杉醇治疗的患者中，紫杉醇重新挑战的实用性。从法国一家癌症中心的本地数据库中，我们回顾性地识别出2008年至2021年间诊断为ER+/HER2-或三阴性乳腺癌并接受治疗的756名患者。其中，58名患者（7.8％）重新接受了紫杉醇治疗。回顾性评估了临床特征、治疗反应率和生存状况，并与仅接受一次紫杉醇治疗的患者进行了比较。与非重新挑战的人群相比，接受紫杉醇重新挑战治疗的患者年龄显著更年轻，整体状态较好，并接受了更多治疗。首次紫杉醇接触导致更好的肿瘤反应，并且停药原因更频繁是由于除进展之外的其他原因，与非重新挑战的人群进行比较。紫杉醇重新挑战导致27.6％的客观反应率和46.6％的临床益处率，中位无进展生存期（PFS）为5.7个月，中位总生存期（OS）为11.6个月。我们还发现，55.2％的重新挑战人群的PFS2 / PFS1比率> 1.3。虽然只有少数MBC患者会受到影响，但紫杉醇重新挑战似乎是一种实用的选择，具有可接受的耐受性和良好的疗效，特别是当这些药物早期已经表现出临床活性和/或由于非进展原因停用时。版权所有©2023作者。 由Elsevier Ltd.出版。保留所有权利。

Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course. In view of the paucity of current literature, we questioned the usefulness of taxane rechallenge in a population of patients previously treated with taxanes in a metastatic setting.From the local database of a French cancer center, we retrospectively identified 756 patients diagnosed with ER+/HER2-, or triple negative MBC, and treated between 2008 and 2021. Among them, 58 patients (7.8%) were rechallenged with taxanes. Clinical characteristics, response rates, and survival were retrospectively evaluated and compared to patients who received taxanes only once.Compared to non-rechallenged population, patients treated with taxane rechallenge were significantly younger, with better general status, and received more treatment. First taxane exposure led to better tumor response and was more frequently discontinued for reasons other than progression, compared to the non-rechallenged population. Taxane rechallenge led to an objective response rate of 27.6%, and a clinical benefit rate of 46.6%, with a median progression-free survival (PFS) of 5.7 months, and a median overall survival (OS) of 11.6 months. We also found a PFS2/PFS1 ratio >1.3 in 55.2% of the rechallenge population.Although only a minority of MBC patients are concerned, taxane rechallenge appears to be a pragmatic option with an acceptable tolerance, and good efficacy, especially when these drugs have shown clinical activity earlier in the disease course, and/or have been stopped for reasons other than progression.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.